Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes
Authors:
Levy AR, Zou D, Risebrough N, Buckstein R, Kim T and Brereton N.
Publication Type:
Journal Article
Publication Name:
Current oncology
Citation:
Levy AR, Zou D, Risebrough N, Buckstein R, Kim T and Brereton N. Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes. Curr Oncol. 2014;21(1):e29-40.
